Department of Neurological Sciences, University of Naples Federico II, Italy.
Immunopharmacol Immunotoxicol. 2008;30(4):1-9. doi: 10.1080/08923970802302753.
We examined the effects of interferon (IFN)beta-1a on interleukin (IL)-12p70 and IL-10 secretion in 27 Relapsing Remitting Multiple Sclerosis (RRMS) patients, divided in responders and non-responders. In responders, IFNbeta-1a does not change the IL-12p70 concentrations, but it leads to a remarkable increase in the IL-10 production. Besides, a high IL-10/IL-12 ratio is demonstrated during the first six months of therapy. In non-responders, there were not significant alterations in the cytokine profile. We suggest that IFNbeta-1a effect in RRMS patients could be explained by its modifying effect on cytokine pattern. Moreover, we propose a possible role of IL-10/IL-12 ratio as a serum marker predictive of favorable clinical course.
我们研究了干扰素（IFN）β-1a 对 27 例复发缓解型多发性硬化症（RRMS）患者白细胞介素（IL）-12p70 和 IL-10 分泌的影响，将这些患者分为应答者和无应答者。在应答者中，IFNβ-1a 不会改变 IL-12p70 浓度，但会导致 IL-10 产生显著增加。此外，在治疗的前六个月期间显示出高的 IL-10/IL-12 比值。在无应答者中，细胞因子谱没有显著变化。我们认为，IFNβ-1a 在 RRMS 患者中的作用可以通过其对细胞因子模式的调节作用来解释。此外，我们提出了 IL-10/IL-12 比值作为预测有利临床病程的血清标志物的可能作用。
